Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and TACE for MVI-positive HCC
NCT04911959Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of adverse events at 8 weeks. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04911959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911959.